Clinical observation of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure
10.3969/j.issn.1005-1678.2017.09.123
- VernacularTitle:美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察
- Author:
Zhongping SHI
;
Haiyue DAI
- Keywords:
clinical efficacy;
coronary heart disease;
heart failure;
trimetazidine;
metoprolol
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(9):278-279
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study and analyze the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure. Methods 80 patients with coronary heart disease and heart failure treated in our hospital from January 2015 to December 2016 were selected and randomly divided into the control group and the experimental group, with 40 cases in each group. The control group received routine treatment, including diuretics and angiotensin converting enzyme inhibitors, and the experimental group was treated with trimetazidine combined with metoprolol. The therapeutic effects of the two groups were compared and analyzed. Results After the corresponding treatment, 5 patients in the experimental group were invalid. In the control group, 14 patients were ineffective. The effective rate of treatment in the experimental group (87.5％) was significantly higher than that in the control group (65.0％), the differences were statistically significant (P<0.05). After treatment, the LVEF in the experimental group was (50.4 ± 7.7)％, and the LVEF in the control group was (45.1 ± 7.0)％. In addition, the LVEDD and LVESD indexes and LVEF in the experimental group were better than those in the control group, the differences were statistically significant (P<0.05). Conclusion The clinical effect of trimetazidine combined with metoprolol in the treatment of coronary heart disease and heart failure is better. It can improve the efficiency of treatment to some extent, and has the significance of further promotion and application.
